Antineoplastic Agents | Clinical Medicine

Overview

Ninja Nerd's comprehensive lecture details antineoplastic agents, starting with cell cycle physiology (G0, G1, S, G2, M phases) and regulation checkpoints. It then categorizes drugs by mechanism: cell cycle specific (S-phase inhibitors like anti-metabolites, G2 inhibitors like Topoisomerase II, M-phase inhibitors like microtubule agents) and non-specific (alkylating agents, anti-tumor antibiotics). The lecture also covers targeted therapies (TKIs, hormonal therapies, monoclonal antibodies) and immunotherapies (immune checkpoint inhibitors), concluding with indications and adverse effects like ototoxicity (cisplatin), pulmonary fibrosis (bleomycin), cardiotoxicity (anthracyclines), and nephrotoxicity (cisplatin).

Key takeaways

Antineoplastic agents target specific cell cycle phases (S-phase inhibitors like anti-metabolites) or are non-specific (alkylating agents, anthracyclines).
Targeted therapies like TKIs (imatinib) and monoclonal antibodies (trastuzumab) inhibit specific oncogenic pathways (BCR-ABL, HER2).
Immunotherapies (anti-PD1, anti-CTLA4) reactivate the T-cell response against cancer cells.
Hormonal therapies (SERMs, aromatase inhibitors) block hormone-driven cancer growth (breast, prostate).
Common adverse effects like ototoxicity (cisplatin), pulmonary fibrosis (bleomycin), and cardiotoxicity (doxorubicin) require specific monitoring.
Leucovorin is a critical rescue agent for methotrexate toxicity, while mesna protects against cyclophosphamide-induced cystitis.

Chapters

0:00 Introduction to Antineoplastic Agents and Cell Cycle Basics

Lecture covers antineoplastic agents, combining Step 1 and Step 2 clinical concepts.
Foundation in cell cycle physiology, regulation, immune, and angiogenic influences.
Focus on drug mechanisms, indications, monitoring, and adverse effects.

2:01 Cell Cycle Phases: G0, G1, S, G2, and M

G0: Quiescent, resting, mature differentiated cells.
G1: Cell growth, organelle production, protein/enzyme synthesis for DNA replication.
S: DNA replication occurs.
G2: Cell size increase, preparation for chromosome separation.
M (Mitosis): Prophase, Metaphase, Anaphase, Telophase; cell division.

10:46 Cell Cycle Specific vs. Non-Specific Agents

Cell cycle specific drugs target G1, S, G2, or M phases.
Cell cycle non-specific drugs affect any phase, including G0.
Cancer cells have a high growth fraction, making them targets for chemotherapy.

13:25 Log Kill Hypothesis and Chemotherapy Targets

Log kill hypothesis: constant fraction of cells die per dose, not a constant number.
Chemotherapy targets highly replicating cells: cancer cells, epidermis, hair follicles, bone marrow.
Adverse effects include hair loss, mucositis, nausea, vomiting, diarrhea, and pancytopenia.

15:53 Cell Cycle Regulation: G1/S Checkpoint

G1/S checkpoint regulated by Cyclin D and Cyclin-Dependent Kinases (CDKs), specifically CDK 4/6.
Retinoblastoma protein (RB) binds E2F; phosphorylation by CDK4/6 releases E2F.
Free E2F acts as a transcription factor, stimulating genes for cell proliferation.

20:52 Upstream Pathways Influencing Cell Cycle (Tyrosine Kinase Receptors)

Growth factors bind to Tyrosine Kinase Receptors (EGFR, ALK) or intracellular kinases (BCR-ABL).
Activation triggers intracellular pathways: PI3K/AKT, RAS/MAPK, STAT.
These pathways stimulate CDK4/6, leading to RB phosphorylation and E2F release.

26:56 Upstream Pathways: JAK2 and HER2 Receptors

JAK2 receptors activated by growth factors, primarily leading to STAT activation.
HER2 receptor activation also stimulates PI3K/AKT, MAPK, and STAT pathways.
Targeting these receptors/pathways can inhibit CDK4/6 and cell proliferation.

30:03 Intracellular Receptors: Estrogen and Androgen Receptors

Steroid hormones (estrogen, androgens) bind intracellular receptors.
Ligand-bound receptors activate CDK4/6, promoting cell cycle progression.
Targeting these pathways is crucial for hormone-sensitive cancers.

33:20 Summary of Upstream Pathways Influencing CDK4/6

Key receptors: Tyrosine Kinases (EGFR, ALK, BCR-ABL), JAK2, HER2, Steroid Receptors.
Downstream pathways: PI3K/AKT/mTOR, RAS/MAPK, STAT.
All converge to influence CDK4/6 activity, driving cell cycle progression.

37:07 Immune Evasion and Angiogenesis in Cancer

Cancer cells evade immune surveillance by altering surface ligands (e.g., PD-L1) or T-cell expression (e.g., CTLA-4).
Cancer cells promote angiogenesis by secreting VEGF to increase blood supply.
Understanding these mechanisms allows for targeted therapeutic interventions.

40:15 Immune Surveillance: T-cell and Cancer Cell Interactions

T-cells interact with cancer cells via TCR/MHC-antigen and CD/MHC.
PD-1 on T-cells interacts with PD-L1 on cancer cells, inhibiting T-cell activity.
CTLA-4 on T-cells competes with CD28 for binding to B7 on APCs, inhibiting T-cell activation.

47:16 Angiogenesis: VEGF and Blood Vessel Formation

Cancer cells secrete VEGF, which binds VEGF receptors on endothelial cells.
This binding stimulates endothelial cell replication and sprouting, forming new blood vessels (angiogenesis).
Increased blood supply fuels tumor growth and metastasis.

51:48 Cell Cycle Inhibitors: S-Phase Specific Agents

S-phase inhibitors target DNA replication.
Anti-metabolites (e.g., methotrexate, 5-FU) inhibit nucleotide synthesis or incorporation.
Topoisomerase I inhibitors (e.g., irinotecan, topotecan) prevent DNA unwinding during replication.

58:36 Cell Cycle Inhibitors: G2 and M-Phase Specific Agents

G2-phase inhibitors include Topoisomerase II inhibitors (etoposide, teniposide) and bleomycin.
M-phase inhibitors (microtubule agents) disrupt mitosis.
Vinca alkaloids (vinblastine, vincristine) inhibit polymerization.
Taxanes (docetaxel, paclitaxel) inhibit depolymerization.

1:02:10 Cell Cycle Non-Specific Agents: Anti-tumor Antibiotics

Anti-tumor antibiotics (e.g., doxorubicin, daunorubicin, dactinomycin) are potent and non-specific.
Bleomycin is an exception, acting specifically in the G2 phase.
Mechanisms include DNA binding, ROS generation, Topoisomerase II inhibition, and intercalation.

1:03:22 Cell Cycle Non-Specific Agents: Alkylating Agents

Alkylating agents (nitrogen mustards, triazines, platinum compounds) are cell cycle non-specific.
They form covalent cross-links within or between DNA strands.
This cross-linking prevents DNA strand separation and replication.

1:05:56 Anti-metabolites: Folate Antagonists (Methotrexate)

Methotrexate (MTX) inhibits dihydrofolate reductase (DHFR).
Inhibiting DHFR reduces tetrahydrofolate, impairing purine and thymidylate synthesis.
This leads to decreased DNA synthesis.

1:13:42 Anti-metabolites: Pyrimidine Antagonists (5-FU, Cytarabine, Gemcitabine)

5-Fluorouracil (5-FU) inhibits thymidylate synthase, blocking thymidine synthesis.
Cytarabine and Gemcitabine are nucleoside analogs incorporated into DNA, terminating elongation.
Gemcitabine also inhibits ribonucleotide reductase at high concentrations.

1:26:48 Anti-metabolites: Purine Antagonists (6-MP, Azathioprine, Cladribine, Fludarabine)

6-Mercaptopurine (6-MP) and Azathioprine are prodrugs converted to 6-thio-IMP.
6-thio-IMP inhibits IMP synthesis and acts as a nucleotide analog.
Cladribine and Fludarabine are ADA-resistant purine analogs used in leukemias.

1:38:37 Ribonucleotide Reductase Inhibitors (Hydroxyurea)

Ribonucleotide reductase converts ribonucleotides to deoxyribonucleotides.
Hydroxyurea is a primary inhibitor, reducing deoxyribonucleotide pool.
Used in sickle cell disease and myeloproliferative disorders.

1:41:52 Topoisomerase Inhibitors: Topoisomerase I Inhibitors

Topoisomerase I inhibitors (irinotecan, topotecan) prevent religation of DNA strands after cutting.
This leads to single-strand DNA breaks and inhibits DNA replication.
Primarily active in the S-phase.

1:50:15 Topoisomerase Inhibitors: Topoisomerase II Inhibitors

Topoisomerase II inhibitors (etoposide, teniposide) prevent religation of double-stranded DNA breaks.
Causes double-strand DNA breaks, unwinding, and torsional stress.
Primarily active in G2 phase and mitosis.

1:55:20 Microtubule Inhibitors: Polymerization Inhibitors (Vinca Alkaloids)

Vinca alkaloids (vinblastine, vincristine) bind beta-tubulin, inhibiting microtubule polymerization.
This prevents spindle formation and chromosome alignment at metaphase.
Acts as an M-phase inhibitor, specifically blocking metaphase.

2:02:31 Microtubule Inhibitors: Depolymerization Inhibitors (Taxanes)

Taxanes (docetaxel, paclitaxel) stabilize microtubules, inhibiting depolymerization.
This prevents shortening of microtubules needed for sister chromatid separation in anaphase.
Acts as an M-phase inhibitor, disrupting anaphase.

2:07:12 Cell Cycle Non-Specific Agents: Anti-tumor Antibiotics (Bleomycin)

Bleomycin is a G2-phase specific anti-tumor antibiotic.
It has a DNA-binding domain and an iron-binding site.
Generates reactive oxygen species, causing DNA damage and fragmentation.

2:13:20 Cell Cycle Non-Specific Agents: Anti-tumor Antibiotics (Anthracyclines)

Anthracyclines (doxorubicin, daunorubicin, dactinomycin) are cell cycle non-specific.
Mechanisms: Topoisomerase II inhibition, ROS generation, DNA intercalation.
Dactinomycin primarily intercalates DNA, while anthracyclines have all three mechanisms.

2:24:03 Cell Cycle Non-Specific Agents: Alkylating Agents

Alkylating agents (nitrogen mustards, triazines, platinum compounds) are cell cycle non-specific.
Form covalent cross-links (interstrand or intrastrand) in DNA.
Inhibits DNA replication by preventing strand separation and polymerase activity.

2:40:26 Targeted Therapies: Protein Kinase Inhibitors (TKIs)

TKIs (e.g., imatinib, osimertinib, alectinib) inhibit specific tyrosine kinases (BCR-ABL, EGFR, ALK).
Inhibiting these kinases downregulates PI3K/AKT, RAS/MAPK, and STAT pathways.
This ultimately inhibits CDK4/6, halting cell cycle progression.

2:51:50 Targeted Therapies: MAPK Pathway and CDK4/6 Inhibitors

RAF inhibitors (e.g., vemurafenib) target the MAPK pathway.
CDK4/6 inhibitors (e.g., palbociclib) directly inhibit CDK4/6 activity.
These therapies block the G1/S checkpoint, preventing cell proliferation.

2:55:18 Hormonal Therapies: Targeting Estrogen and Androgen Pathways

SERMs (tamoxifen, raloxifene) block estrogen receptor binding.
GnRH agonists (leuprolide) and antagonists (degarelix) reduce estrogen/testosterone production.
Aromatase inhibitors (anastrozole, letrozole) block androgen-to-estrogen conversion.
Anti-androgens (enzalutamide) block androgen receptor binding.

3:12:12 Monoclonal Antibodies: Targeting Receptors (Cetuximab, Trastuzumab)

Monoclonal antibodies (ending in -mab) target cell surface receptors.
Cetuximab targets EGFR, blocking downstream signaling (PI3K/AKT, RAS/MAPK, STAT).
Trastuzumab targets HER2, inhibiting proliferation pathways.

Summary, takeaways, and chapters were generated by AI from the video's transcript and may contain errors. The video belongs to its creator, Ninja Nerd.